The European patent has been validated in several European countries including France, Germany, Ireland, Spain, Sweden, Switzerland and the UK.
Neuralstem’s patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.
Richard Garr, Neuralstem’s CEO, said: “We are pleased to see our core technology patent validated in these European countries. We expect this to be the first of many as our entire patent portfolio makes its way through the European process.”